Predicting early response to atezolizumab plus bevacizumab
Part of Cancer, Digestive system clinical trials.
This study tries to predict how well your cancer responds early after starting a treatment called atezolizumab plus bevacizumab. If you qualify, your information may help doctors choose better treatments sooner for people with advanced liver cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced hepatocellular carcinoma (advanced liver cancer).
- Your planned first treatment is atezolizumab plus bevacizumab.
- You agree to take part in the study.
- You do not have a history of severe allergy to contrast dye used in scans.
- You do not have serious other health problems that could limit organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding atezolizumab and bevacizumab after complete liver cancer surgery can lower the chance the cancer comes back. It also uses “multi-omics” tests (special lab tests on your tissue/blood) to help predict who is more likely to respond or resist treatment.
This trial studies whether a combination of immune therapy (atezolizumab) and a blood-vessel-targeting drug (bevacizumab) works better than a standard procedure called TACE for people with intermediate-stage liver cancer (HCC). It may help shrink tumors and help patients live longer with fewer complications.
This Phase 2 trial tests whether atezolizumab plus bevacizumab, given along with liver cancer treatment procedures (TACE/HAIC), can help people with advanced liver cancer that cannot be removed by surgery. It mainly looks at whether these medicines can control the cancer more effectively and safely.
This trial combines three medications—an immunotherapy (atezolizumab), a drug that blocks blood vessel growth (bevacizumab), and one that reduces inflammation (tocilizumab)—to see if they work together against advanced liver cancer. The goal is to slow cancer growth and possibly shrink the tumor.
This study is looking at how well a combination of two drugs (atezolizumab and bevacizumab) works for people with liver cancer that can't be removed by surgery. The goal is to learn how to predict the best response using lab tests and CT scans.
This study looks at whether certain blood markers can predict how well the combination of atezolizumab and bevacizumab works for people with advanced liver cancer. It aims to find out if these markers can help guide treatment decisions.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.